This Week in GLP-1s / August 16-22, 2026
UC Berkeley Researchers Discover Muscle-Sparing Obesity Treatment
Lead item
UC Berkeley Researchers Discover Muscle-Sparing Obesity Treatment
A new preclinical treatment burns fat while preserving lean muscle mass, addressing a major limitation of current GLP-1 therapies. New data shows a 34% drop in bariatric surgeries and obesity drugs rising to 25% of the total pharmaceutical pipeline. Muscle loss (sarcopenia) is the primary clinical and patient concern with GLP-1 therapy; this represents a major potential scientific breakthrough.
Muscle loss (sarcopenia) is the primary clinical and patient concern with GLP-1 therapy; this represents a major potential scientific breakthrough.
Top stories
Wells Fargo Report: GLP-1s Reshaping Healthcare Economics and Surgery Volumes
New data shows a 34% drop in bariatric surgeries and obesity drugs rising to 25% of the total pharmaceutical pipeline.
Comprehensive industry impact report defining the 'strategic reset' required for healthcare operators in the GLP-1 era.
US States Reject Trump Administration Medicaid GLP-1 Price Deal
Most state Medicaid programs are rejecting a federal deal for lower-priced weight-loss drugs due to budgetary and eligibility constraints.
High-impact policy story regarding the viability of federal price-cutting initiatives for obesity medications.
Novo Nordisk Launches OASIS 5 Trial for Lower-Dose Oral Wegovy
The Phase 3 trial seeks to identify the lowest effective maintenance dose of oral semaglutide to optimize manufacturing capacity.
Strategic move to solve supply constraints by reducing the amount of API required per patient for long-term use.
Lancet Consensus Statement on GLP-1 Guidelines Released
Leading experts define new standards for GLP-1 prescribing, emphasizing their transformative role beyond weight management.
Sets the medical standard of care that will drive clinical decision-making and payer coverage policies.
FDA Renews Endocrinologic and Cardiovascular Drug Advisory Committees
Renewal of these critical committees signals a heavy upcoming slate of pipeline reviews for obesity and renal therapies.
Administrative necessity that confirms the regulatory machinery is preparing for major new drug applications in H2 2026.